European Central Bank President Jean-Claude Trichet said he's "concerned" about the euro's appreciation - - his most direct comments since the euro's rise to record levels above $1.50 versus the dollar, Bloomberg News reported Monday.
The euro rose about one-half cent to $1.5407 versus the dollar before retreating to $1.5351 in Monday afternoon trading.
``We're concerned about excessive exchange-rate moves in the present circumstances,'' Trichet told Bloomberg News in Basel, Switzerland Monday. It's the first time Trichet has specifically expressed worry about the currency since November 2007, when he said he opposed "brutal" moves.
Amid a U.S. economic slowdown and U.S. Federal Reserve efforts to stimulate the world's largest economy with interest rate cuts, the ECB has maintained a status-quo monetary policy, keeping its benchmark refinance rate a 4%. That sand-pat policy has contributed to a flight out of the dollar and into the euro, which increases the cost of euro-zone exports to the U.S., if European companies raise prices to compensate for the dollar's depreciation. The euro has risen more than 5% versus the dollar this year, and is up more than 90% since 2001.
Forex Analysis: Trichet's comments came as a surprise. A hawk, Trichet has heretofore underscored the need for monetary policy discipline to contain euro-zone inflation. Further, Trichet has sided with the monetarists' school that argues that foreign exchange rate changes should be market-determined, so long as they are gradual. In addition, the ECB has never intervened in the currency markets to weaken the euro, and last intervened to strengthen it in 2000. No change is expected in that policy given Monday's comments, barring a sudden, large fall in the dollar / rise in the euro.
Last updated: February 13, 2012: 09:00 AM
Hot Stocks
DailyFinance Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
Benzinga Headlines
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
TheFlyOnTheWall.com Headlines
- Chesapeake Energy volatility flat at 42 into financial plan
- Gardner Denver shares attractive at current levels, says RBC Capital
- Parkway Properties completes purchase of Phoenix Asset
- Total Q4 results in-line with expectations, says Nomura
- Mattress Firm downgraded to Market Perform from Outperform at Raymond James
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

